This clinical trial is focused on studying different treatment strategies for patients who need support from a machine called Extracorporeal Membrane Oxygenation, or ECMO. ECMO is used in serious conditions like Respiratory Insufficiency, Respiratory Failure, Circulatory Failure, and Acute Respiratory Distress Syndrome. The study will compare three medications that help prevent blood clots, which are a common risk during ECMO therapy. These medications are Unfractionated Heparin, Argatroban, and Low-molecular-weight Heparin (also known as Enoxaparin).
The purpose of the study is to see how these medications affect the occurrence of blood clots during ECMO therapy. Participants will be randomly assigned to receive one of the three medications. The study will monitor the incidence of blood clots, such as pulmonary embolism and deep vein thrombosis, as well as any bleeding events. The study will last for a period of up to six months for each participant.
Throughout the study, participants will receive regular check-ups to monitor their health and the effectiveness of the medication they are receiving. The goal is to determine which medication is most effective in preventing blood clots without causing significant bleeding. This information will help improve treatment strategies for patients requiring ECMO support in the future.



Austria